Angiogenin outperforms VEGF, EPCs and CECs in predicting Dukes' and AJCC stage in colorectal cancer

European Journal of Clinical Investigation

Volumn 43, Issue 8, 2013, Pages 801-808

  Ramcharan, Sean K ^a,b   Lip, Gregory Y H ^a   Stonelake, Paul S ^b   Blann, Andrew D ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b RUSSELLS HALL HOSPITAL   (United Kingdom)

Author keywords

Angiogenin; Circulating endothelial cells; Colorectal cancer; Endothelial progenitor cells; Von Willebrand factor

Indexed keywords

ANGIOGENIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; VASCULOTROPIN;

AGED; ARTICLE; CANCER STAGING; CIRCULATING ENDOTHELIAL CELL; CLINICAL DECISION MAKING; COLORECTAL CANCER; CONTROLLED STUDY; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM;

EID: 84880762969     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12108     Document Type: Article

References (49)

1. Cancer Research UK. http://info.cancerresearchuk.org/utilities/atozindex/atoz-bowel-cancer.
2. http://www.statistics.gov.uk/hub/health-social-care/health-of-the-population/causes-of-death/index.html.
3. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
4. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995;55:3964-8.
5. Shimoyama S, Yamasaki K, Kawahara M, Kaminishi M. Increased serum angiogenin concentration in colorectal cancer is correlated with cancer progression. Clin Cancer Res 1999;5:1125-30.
6. Koutras AK, Starakis I, Kyriakopoulou U, Katsaounis P, Nikolakopoulos A, Kalofonos HP. Targeted therapy in colorectal cancer: current status and future challenges. Curr Med Chem 2011;18:1599-612.
7. Gil-Bazo I, Catalán Goni V, Alonso Gutiérrez A, Rodríguez Rodríguez J, Páramo Fernández JA, de la Cámara Gómez J et al. Impact of surgery and chemotherapy on von Willebrand factor and vascular endothelial growth factor levels in colorectal cancer. Clin Transl Oncol 2005;7:150-5.
8. Sato H, Usuda N, Kuroda M, Hashimoto S, Maruta M, Maeda K. Significance of serum concentrations of E-selectin and CA19-9 in the prognosis of colorectal cancer. Jpn J Clin Oncol 2010;40:1073-80.
9. Dome D, Dobos J, Tovari J, Paku S, Kovacs G, Ostoros G et al. Circulating bone marrow-derived endothelial progenitor cells: characterization, mobilization, and therapeutic considerations in malignant disease. Cytometry A 2008;73:186-93.
10. Rowand JL, Martin G, Doyle GV, Miller MC, Pierce MS, Connelly MC et al. Endothelial cells in peripheral blood of healthy subjects and patients with metastatic carcinomas. Cytometry A 2007;71:105-13.
11. Fürstenberger G, von Moos R, Lucas R, Thürlimann B, Senn HJ, Hamacher J et al. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 2006;94:524-31.
12. Beerepoot LV, Mehra N, Vermaat JS, Zonnenberg BA, Gebbink MF, Voest EE. Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 2004;15:139-45.
13. Blann AD, Pretorius A. Circulating endothelial cells and endothelial progenitor cells: two sides of the same coin, or two different coins? Atherosclerosis 2006;188:12-8.
14. Ding YT, Kumar S, Yu DC. The role of endothelial progenitor cells in tumour vasculogenesis. Pathobiology 2008;75:265-73.
15. Mancuso P, Bertolini F. Circulating endothelial cells as biomarkers in clinical oncology. Microvasc Res 2010;79:224-8.
16. Blann AD, Ramcharan KS, Stonelake PS, Luesley D, Lip GY. The angiome: a new concept in cancer biology. J Clin Pathol 2011;64:637-43.
17. Ramcharan KS, Lip GY, Stonelake PS, Blann AD. The endotheliome: a new concept in vascular biology. Thromb Res 2011;128:1-7.
18. Dukes CE. The classification of cancer of the rectum. J Pathol Bacteriol 1932;35:323.
19. Astler VB, Coller FA. The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 1954;139:846.
20. Edge SB. American Joint Committee on Cancer: AJCC Cancer Staging Manual, 7th Edn. New York: Springer; 2010.
21. Sobin LH, Compton CC. TNM seventh edition: what's new, what's changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer. Cancer 2010;116:5336-9.
22. Goon PK, Lip GY, Stonelake PS, Blann AD. Circulating endothelial cells and circulating progenitor cells in breast cancer: relationship to endothelial damage/dysfunction/apoptosis, clinicopathologic factors, and the Nottingham Prognostic Index. Neoplasia 2009;11:771-9.
23. Blann AD, Balakrishnan B, Shantsila E, Ryan P, Lip GY. Endothelial progenitor cells and circulating endothelial cells in early prostate cancer: a comparison with plasma vascular markers. Prostate 2011;71:1047-53.
24. Altman DG. Practical Statistics for Medical Research. London: Chapman and Hall; 1991.
25. Kemeny N, Braun DW Jr. Prognostic factors in advanced colorectal carcinoma. Importance of lactic dehydrogenase level, performance status, and white blood cell count. Am J Med 1983;74:786-94.
26. Schisterman EF, Perkins NJ, Liu A, Bondell H. Optimal cut-point and its corresponding Youden Index to discriminate individuals using pooled blood samples. Epidemiology 2005;16:73-81.
27. Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:32-5.
28. Matsusaka S, Mishima Y, Suenaga M, Terui Y, Kuniyoshi R, Mizunuma N et al. Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab. Cancer 2011;117:4026-32.
29. Ronzoni M, Manzoni M, Mariucci S, Loupakis F, Brugnatelli S, Bencardino K et al. Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients. Ann Oncol 2010;21:2382-9.
30. Li B, Sharpe EE, Maupin AB, Teleron AA, Pyle AL, Carmeliet P et al. VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J 2006;20:1495-7.
31. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999;18:3964-72.
32. Duda DG, Cohen KS, di Tomaso E, Au P, Klein RJ, Scadden DT et al. Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J Clin Oncol 2006;24:1449-53.
33. Gupta M. Circulating endothelial cells and circulating endothelial cell progenitors as surrogate markers for determining response to antiangiogenic agents. Clin Colorectal Cancer 2007;6:337-8.
34. Fujisaki K, Mitsuyama K, Toyonaga A, Matsuo K, Tanikawa K. Circulating vascular endothelial growth factor in patients with colorectal cancer. Am J Gastroenterol 1998;93:249-52.
35. Kumar H, Heer K, Lee PW, Duthie GS, MacDonald AW, Greenman J et al. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 1998;4:1279-85.
36. Werther K, Christensen IJ, Brünner N, Nielsen HJ. Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group. Eur J Surg Oncol 2000;26:657-62.
37. De Vita F, Orditura M, Lieto E, Infusino S, Morgillo F, Martinelli E et al. Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer 2004;100:270-8.
38. Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 1998;77:956-64.
39. Webb NJ, Bottomley MJ, Watson CJ, Brenchley PE. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Science 1998;94:395-404.
40. Ross R, Vogel A. The platelet-derived growth factor. Cell 1978;14:203-10.
41. Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost 2011;9:237-49.
42. Woywodt A, Gerdes S, Ahl B, Erdbruegger U, Haubitz M, Weissenborn K. Circulating endothelial cells and stroke: influence of stroke subtypes and changes during the course of disease. J Stroke Cerebrovasc Dis 2012;21:452-8.
43. Bellows CF, Zhang Y, Chen J, Frazier ML, Kolonin MG. Circulation of progenitor cells in obese and lean colorectal cancer patients. Cancer Epidemiol Biomarkers Prev 2011;20:2461-8.
44. Fett JW, Strydom DJ, Lobb RR, Alderman EM, Bethune JL, Riordan JF et al. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry 1985;24:5480-6.
45. Rykala J, Przybylowska K, Majsterek I, Pasz-Walczak G, Sygut A, Dziki A et al. Angiogenesis markers quantification in breast cancer and their correlation with clinicopathological prognostic variables. Pathol Oncol Res 2011;17:809-17.
46. Eppenberger U, Kueng W, Schlaeppi JM, Roesel JL, Benz C, Mueller H et al. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J Clin Oncol 1998;16:3129-36.
47. Landt S, Wehling M, Heidecke H, Jeschke S, Korlach S, Stöblen F et al. Prognostic significance of angiogenic factors in uterine cervical cancer. Anticancer Res 2011;31:2589-95.
48. Fang S, Repo H, Joensuu H, Orpana A, Salven P. High serum angiogenin at diagnosis predicts for failure on long-term treatment response and for poor overall survival in non-Hodgkin lymphoma. Eur J Cancer 2011;47:1708-16.
49. Paulinska P, Spiel A, Jilma B. Role of von Willebrand factor in vascular disease. Hamostaseologie 2009;29:32-8.